Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Integra LifeSciences Holdings Corporation/ 10-K

Annual Report · 10-K

Integra LifeSciences Holdings Corporation

IARTNASDAQEQUITYCurrent

Annual Report

Filed Feb 22, 2023Accepted Feb 22, 2023, 4:12 PM ESTCIK 917520Accession 0000917520-23-000015
View company →Permanent SEC source ↗
Share

Company context

Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care.

Current securities

IARTNASDAQ · EQUITY · Current

Recent company filings

  1. Regulation FD DisclosureOct 9, 2026
  2. Results of Operations and Financial Condition · Regulation FD DisclosureOct 2, 2026
  3. Regulation FD DisclosureSep 8, 2026
  4. SCHEDULE 13G/A - filed by PARADIGM CAPITAL MANAGEMENT INC/NY regarding INTEGRA LIFESCIENCES HOLDINGS CORPAug 13, 2026
  5. SCHEDULE 13G - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding INTEGRA LIFESCIENCES HOLDINGS CORPJul 31, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.